# US 2026/0183242 A1 · Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0183242 A1
- Document ID: US20260183242A1
- Status: Published application
- Kind: A1
- Application number: 19/544,782
- Filed: 2026-02-19
- Published: 2026-07-02
- Earliest claimed: 2023-08-30
- Assignees: Entera Bio Ltd.
- Applicants: Entera Bio Ltd.
- Inventors: Gregory BURSHTEIN; Constantin ITIN; Hillel GALITZER
- Web page: https://patentgrep.com/patent/US20260183242A1

## CPC

- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61P 5/18: of the parathyroid hormones
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 31/4172: Imidazole-alkanecarboxylic acids, e.g. histidine
- A61K 38/26: Glucagons
- A61K 38/29: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition is described herein, which comprises a therapeutically active agent, an absorption enhancer, a polymer comprising a plurality of alkaline groups, and a non-polymeric (small molecule) proton-accepting agent. The absorption enhancer is preferably a substituted fatty acid or a salt thereof. Further described herein are methods of treating a condition treatable by the therapeutically active agent, comprising orally administering the pharmaceutical composition.

## Claims

### Claim 1

An oral pharmaceutical composition comprising a therapeutically active agent, an absorption enhancer comprising a substituted fatty acid or a salt thereof, a polymer comprising a plurality of alkaline groups, and at least one proton accepting non-polymeric agent, wherein a concentration of the polymer in the composition is at least 10 weight percent of the total weight of the composition and wherein the ratio (by weight) of the proton accepting non-polymeric agent to the absorption enhancer ranges from 0.2:1 to 1:1.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the alkaline groups in the polymer are carboxylate groups and/or amine groups.

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 2)

The composition of claim 2, wherein at least a portion of the carboxylate groups in the polymer are in a form of a sodium salt.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the absorption enhancer is NAC (8-N-(2-hydroxybenzoyl)aminocaprylic acid), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), or 4-CNAB (4-N-(2-hydroxy-4-chlorobenzoyl)aminobutanoic acid) or salts thereof of any of the above.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the absorption enhancer comprises NAC or a salt thereof.

### Claim 8 (depends on 7)

The composition of claim 7, wherein a concentration of the absorption enhancer is at least 50 weight percent of the total weight of the composition.

### Claim at position 8

9-12. (canceled)

### Claim 13 (depends on 1)

The composition of claim 1, wherein the polymer comprises a polysaccharide.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the polysaccharide is a starch derivative and a cellulose derivative.

### Claim at position 11

15-16. (canceled)

### Claim 17 (depends on 14)

The composition of claim 14, wherein the polymer is sodium starch glycolate or croscarmellose sodium.

### Claim at position 13

18-20. (canceled)

### Claim 21 (depends on 1)

The composition of claim 1, wherein the at least one proton-accepting non-polymeric agent features a pKa of at least 5.

### Claim 22

(canceled)

### Claim 23 (depends on 21)

The composition of claim 21, wherein the at least one proton accepting non-polymeric agent is an antacid, an amino acid, a salt of a fatty acid, or a combination thereof.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the antacid is calcium carbonate, calcium gluconate, calcium citrate, sodium carbonate, sodium bicarbonate, sodium hydroxide, potassium carbonate, potassium bicarbonate, potassium gluconate, potassium citrate, potassium hydroxide, magnesium carbonate, magnesium gluconate, magnesium citrate, magnesium hydroxide, magnesium oxide, aluminum carbonate, aluminum gluconate, aluminum citrate, aluminum hydroxide, or any combinations thereof.

### Claim 25 (depends on 24)

The composition of claim 24, wherein the at least one proton-accepting non-polymeric agent comprises sodium carbonate or potassium carbonate.

### Claim at position 19

26-27. (canceled)

### Claim 28 (depends on 25)

The composition of claim 25, wherein the at least one proton accepting non-polymeric agent is histidine, arginine, lysine, an analog thereof, or any combinations thereof.

### Claim at position 21

29-30. (canceled)

### Claim 31 (depends on 23)

The composition of claim 23, wherein the salt of a fatty acid is a salt of a medium-chain fatty acid, having from 8 to 10 carbon atoms in length.

### Claim 32 (depends on 31)

The composition of claim 31, wherein the salt of a fatty acid is sodium octanoate, sodium decanoate, or a combination thereof.

### Claim at position 24

33-34. (canceled)

### Claim 35 (depends on 1)

The composition of claim 1, wherein a total concentration of the at least one proton-accepting non-polymeric agent in the composition is at least 20 weight percent of the total weight of the composition.

### Claim 36 (depends on 1)

The composition of claim 1, wherein a Cmax of the composition upon oral administration is at least 50% greater than a Cmax of a corresponding composition without the polymer and the proton accepting non-polymeric agent and/or
wherein a bioavailability of the composition upon oral administration is at least 50% greater than a bioavailability of a corresponding composition without the polymer and the proton accepting non-polymeric agent.

### Claim 37

(canceled)

### Claim 38 (depends on 1)

The composition of claim 1, wherein the therapeutically active agent has a molecular weight in a range of 0.5 kDa to 100 kDa.

### Claim 39

(canceled)

### Claim 40 (depends on 38)

The composition of claim 38, wherein the therapeutically active agent is a polypeptide or a nucleic acid.

### Claim 41 (depends on 40)

The composition of claim 40, wherein the polypeptide is a parathyroid hormone (PTH), a long-acting analog of PTH, a fragment of PTH, a long-acting analog of a fragment of PTH, GLP-1 (glucagon-like peptide-1) or a long-acting analog thereof, a GLP-1 receptor agonist or a long-acting analog thereof, a GLP-2 (glucagon-like peptide-2) or a long-acting analog thereof, a GLP-2 receptor agonist or a long-acting analog thereof, GLP-1 receptor/glucagon receptor dual agonist or a long-acting analog thereof, a GIP receptor/GLP-1 receptor dual agonist or a long-acting analog thereof, glucagon receptor/GIP receptor/GLP-1 receptor triple agonist or a long-acting analog thereof, GLP-2 receptor/glucagon receptor dual agonist or a long-acting analog thereof, GLP-2 receptor/GLP-1 receptor dual agonist or a long-acting analog thereof, GLP-2 receptor/GIP receptor dual agonist or a long-acting analog thereof, or oxyntomodulin or a long-acting analog thereof.

### Claim 42 (depends on 41)

The composition of claim 41, wherein the polypeptide is characterized by isoelectric point (pl) of at least 8.5.

### Claim at position 33

43-44. (canceled)

### Claim 45 (depends on 1)

A unit dosage form comprising the composition of claim 1.

### Claim 46 (depends on 45)

The unit dosage form of claim 45, wherein an amount of the alkaline groups in the unit dosage form is at least 0.03 millimoles.

### Claim 47 (depends on 46)

The unit dosage form of claim 46, wherein the unit dosage form comprises at least 50 mg of the absorption enhancer.

### Claim 48 (depends on 47)

The unit dosage form of claim 47, wherein the unit dosage form comprises at least 10 mg of the proton-accepting non-polymeric agent.

### Claim 49 (depends on 48)

The unit dosage form of claim 48, wherein the unit dosage form comprises one or more tablet(s).

### Claim 50 (depends on 1)

A method of treating a condition treatable by the composition of claim 1, the method comprising orally administering the composition to a subject in need thereof.
